Grace Therapeutics (GRCE) Other Accumulated Expenses (2024 - 2026)

Grace Therapeutics has reported Other Accumulated Expenses for 3 years, with the latest figure at $527000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses rose 411.65% year-over-year to $527000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $527000.0 (up 411.65% YoY) and the FY2026 annual result came in at $527000.0, up 411.65% from the prior year.
• Other Accumulated Expenses rose to $527000.0 in Q1 2026 per GRCE's latest filing, from $195000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $814000.0 in Q4 2024 and troughed at $35000.0 in Q3 2025.
• A 3-year average of $297375.0 and a median of $149000.0 in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses tumbled 94.41% in 2025, then soared 411.65% in 2026.
• Over 3 years, Other Accumulated Expenses stood at $814000.0 in 2024, then slumped by 76.04% to $195000.0 in 2025, then jumped by 170.26% to $527000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $527000.0, $195000.0, and $35000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.